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This document reflects emerging clinical and scientific advances on the date issued, and is subject to change.  The information 
should not be construed as dictating an exclusive course of treatment or procedure to be followed.  Local institutions can dictate 
amendments to these opinions.  They should be well documented if modified at the local level.  None of these contents may be 
reproduced in any form without prior written permission of the SOGC.
Abstract
Objective: To provide guidelines for the use of antenatal magnesium 
sulphate (MgSO4) for fetal neuroprotection of the preterm infant .
Options: Antenatal MgSO4 administration should be considered for 
fetal neuroprotection when women present at ≤ 31+6 weeks 
with imminent preterm birth, defined as a high likelihood of birth 
because of active labour with cervical dilatation ≥ 4 cm, with 
or without preterm pre-labour rupture of membranes, and/or 
planned preterm birth for fetal or maternal indications .
 There are no other known fetal neuroprotective agents .
Outcomes: The outcomes measured are the incidence of cerebral 
palsy (CP) and neonatal death .
Evidence: Published literature was retrieved through searches of 
PubMed or Medline, CINAHL, and the Cochrane Library in May 
2010, using appropriate controlled vocabulary and key words 
(magnesium sulphate, cerebral palsy, preterm birth) . Results 
were restricted to systematic reviews, randomized controlled 
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trials, and relevant observational studies . There were no date 
or language restrictions . Searches were updated on a regular 
basis and incorporated in the guideline to August 2010 . Grey 
(unpublished) literature was identified through searching the 
websites of health technology assessment and health technology 
assessment-related agencies, clinical practice guideline 
collections, clinical trial registries, and national and international 
medical specialty societies .
Values: The quality of evidence was rated using the criteria described 
in the Report of the Canadian Task Force on Preventive Health 
Care (Table 1) .
Benefits, harms, and costs: Antenatal magnesium sulphate for fetal 
neuroprotection reduces the risk of “death or CP” (RR 0 .85; 
95% CI 0 .74 to 0 .98; 4 trials, 4446 infants), “death or moderate-
severe CP” (RR 0 .85; 95% CI 0 .73 to 0 .99; 3 trials, 4250 infants), 
“any CP” (RR 0 .71; 95% CI 0 .55 to 0 .91; 4, trials, 4446 infants), 
“moderate-to-severe CP” (RR 0 .60; 95% CI 0 .43 to 0 .84; 3 
trials, 4250 infants), and “substantial gross motor dysfunction” 
(inability to walk without assistance) (RR 0 .60; 95% CI 0 .43 
to 0 .83; 3 trials, 4287 women) at 2 years of age . Results were 
consistent between trials and across the meta-analyses . There 
is no anticipated significant increase in health care-related costs, 
because women eligible to receive antenatal MgSO4 will be 
judged to have imminent preterm birth .
Validation: Australian National Clinical Practice Guidelines were 
published in March 2010 by the Antenatal Magnesium Sulphate 
for Neuroprotection Guideline Development Panel . Antenatal 
MgSO4 was recommended for fetal neuroprotection in the 
same dosage as recommended in these guidelines . However, 
MgSO4 was recommended only at < 30 weeks’ gestation, based 
on 2 considerations . First, no one gestational age subgroup 
was considered to show a clear benefit . Second, in the face of 
uncertainty, the committee felt it was prudent to limit the impact 
of their clinical practice guidelines on resource allocation . Also 
in March 2010, the American College of Obstetricians and 
Gynecologists issued a Committee Opinion on MgSO4 for fetal 
neuroprotection . It stated that, “the available evidence suggests 
that magnesium sulphate given before anticipated early preterm 
birth reduces the risk of cerebral palsy in surviving infants .” No 
official opinion was given on a gestational age cut-off, but it was 
recommended that physicians develop specific guidelines around 
the issues of inclusion criteria, dosage, concurrent tocolysis, and 
monitoring in accordance with one of the larger trials .
Sponsors: Canadian Institutes of Health Research (CIHR) .
Summary Statement
1 . “Imminent preterm birth” is defined as a high likelihood of birth  
due to one or both of the following conditions (II-2):
• Active labour with ≥ 4 cm of cervical dilation, with or without 
PPROM .
• Planned preterm birth for fetal or maternal indications .
Recommendations
1 .  For women with imminent preterm birth (≤ 31+6 weeks), antenatal 
magnesium sulphate administration should be considered for fetal 
neuroprotection . (I-A)
2 .  Although there is controversy about upper gestational age, 
antenatal magnesium sulphate for fetal neuroprotection should be 
considered from viability to ≤ 31+6 weeks . (II-1B)
3 .  If antenatal magnesium sulphate has been started for fetal 
neuroprotection, tocolysis should be discontinued . (III-A)
4 .  Magnesium sulphate should be discontinued if delivery is no 
longer imminent or a maximum of 24 hours of therapy has been 
administered . (II-2B)
5 .  For women with imminent preterm birth, antenatal magnesium 
sulphate for fetal neuroprotection should be administered as 
a 4g IV loading dose, over 30 minutes, followed by a 1g/hr 
maintenance infusion until birth . (II-2B)
6 .  For planned preterm birth for fetal or maternal indications, 
magnesium sulphate should be started, ideally within 4 hours 
before birth, as a 4g IV loading dose, over 30 minutes, followed by 
a 1g/hr maintenance infusion until birth . (II-2B)
7 .  There is insufficient evidence that a repeat course of antenatal 
magnesium sulphate for fetal neuroprotection should be 
administered . (III-L)
8 .  Delivery should not be delayed in order to administer antenatal 
magnesium sulphate for fetal neuroprotection if there are maternal 
and/or fetal indications for emergency delivery . (III-E)
9 .  When magnesium sulphate is given for fetal neuroprotection, 
maternity care providers should use existing protocols to monitor 
women who are receiving magnesium sulphate for preeclampsia/
eclampsia . (III-A)
10 .  Indications for fetal heart rate monitoring in women receiving 
antenatal magnesium sulphate for neuroprotection should follow 
the fetal surveillance recommendations of the SOGC 2007 Fetal 
Health Surveillance: Antepartum and Intrapartum Consensus 
Guideline . (III-A)
11 .  Since  magnesium sulphate has the potential to alter the 
neonate’s neurological evaluation, causing hypotonia or apnea, 
health care providers caring for the neonate should have an 
increased awareness of this effect . (III-C)
BACKGROUND
The Importance of Preterm Birth
The Canadian preterm birth rate overall reached 8.2 % of  live births in 2004, with births at < 32 weeks 
representing 1.2 % of  live births in Canada.1 The survival 
of  infants born preterm has improved with interventions 
such as antenatal corticosteroids and surfactant. However, 
survival has been associated with substantial risk of  medical 
and neurodevelopmental impairment.
ABBREVIATIONS
APH  antepartum hemorrhage
CP   cerebral palsy
IQR  interquartile range
IUGR  intrauterine growth restriction
NNT  number needed to treat
PPROM  preterm pre-labour rupture of membranes
PTL  preterm labour
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Two identified patterns of  injury appear to underlie the 
central nervous system complications of  preterm infants: 
(1) intraventricular hemorrhage and (2) white matter injury. 
Severe intraventricular hemorrhage (grades 3 and 4) is reliably 
detected by ultrasound and occurs primarily among babies 
who are born at or before 28 weeks’ gestation. Although the 
incidence of  severe intraventricular hemorrhage is highest 
at 24 to 25 weeks, severe intraventricular hemorrhage is still 
a relevant problem up to 28 weeks, because there are more 
births at 26 to 28 weeks than at 24 to 25 weeks. MRI is 
required for reliable detection of  white matter injury, which 
has a peak prevalence at 28 weeks. Its severity is associated 
with adverse motor and cognitive outcomes.2
Clinically, the most frequent adverse neurological outcomes 
associated with preterm birth are cerebral palsy and cognitive 
impairment. Other adverse outcomes include blindness, 
deafness, developmental delay, and/or other neurological 
impairment. More than 50% of  very preterm babies suffer 
from learning or motor disabilities or school difficulties, 
compared with about 20% of  normal birthweight controls.3
The Importance of Cerebral Palsy
Cerebral palsy is a symptom complex of  non-progressive 
motor impairment syndromes secondary to brain injury or 
anomalies arising in early development.4 The typical signs of  
CP include spasticity, movement disorders, muscle weakness, 
ataxia, and rigidity. There are 4 main types of  cerebral palsy:
1. Spastic (increased muscle tone)
2. Athetoid or dyskinetic (slow, uncontrolled movements)
3. Ataxic (problems with balance and depth perception)
4. Mixed
The most common pattern is spasticity plus athetoid move-
ments.5 CP can be reliably diagnosed by the age of  2 years.
The prevalence of  CP is 2 to 2.5 per 1000 live births.6 The risk 
of  CP is highest at earlier gestational ages. Compared with 
infants born at term, infants born preterm have a CP risk 
that is approximately 3-fold higher at 34 to 36 weeks,7 8-fold7 
to 14-fold8 higher at 30 to 33 weeks, 46-fold higher at 28 to 
30 weeks,8 and as high as 30-fold4 to 80-fold8 higher at < 28 
weeks.9 The gestational age-related risk is associated, in part, 
with very low birth weight (i.e., < 1500 g) and intraventricular 
hemorrhage.10–12 Multiples are also at heightened CP risk.13
Temporal trends in the prevalence of  CP among infants 
born very preterm are a matter of  controversy. Rates have 
been reported to be both falling14,15 and rising,10,16 possibly 
because perinatal mortality rates are decreasing, so that the 
rate of  “death or CP” among infants born at < 30 weeks 
has appeared to be stable.6
What is agreed upon, however, is that the economic 
burden associated with CP is enormous. The US Centers 
for Disease Control and Prevention estimate that lifetime 
health care, productivity, and social costs for a person with 
CP are US$921 000 (2003).17
There is no known cure for CP, which makes effective 
preventive measures of  primary importance. To date, no 
Table 1. Key to evidence statements and grading of recommendations, using the ranking of the Canadian Task Force  
on Preventive Health Care
Quality of evidence assessment* Classification of recommendations†
I:       Evidence obtained from at least one properly randomized  
controlled trial
A .  There is good evidence to recommend the clinical preventive action
II-1:   Evidence from well-designed controlled trials  without    
randomization
B .  There is fair evidence to recommend the clinical preventive action
II-2:   Evidence from well–designed cohort (prospective or   
retrospective) or case–control studies, preferably from   
more than one centre or research group
C .  The existing evidence is conflicting and does not allow to make a 
recommendation for or against use of the clinical preventive action; 
however, other factors may influence decision-making
II-3:   Evidence obtained from comparisons between times or  
places with or without the intervention . Dramatic results in 
uncontrolled experiments (such as the results of treatment with 
penicillin in the 1940s) could also be included in this category
D .  There is fair evidence to recommend against the clinical preventive action
E .   There is good evidence to recommend against the clinical preventive 
action
III:     Opinions of respected authorities, based on clinical experience, 
descriptive studies, or reports of expert committees
L .   There is insufficient evidence (in quantity or quality) to make 
a recommendation; however, other factors may influence 
decision-making
* The quality of evidence reported in these guidelines has been adapted from The Evaluation of Evidence criteria described in the Canadian Task Force on 
Preventive Health Care .47 
† Recommendations included in these guidelines have been adapted from the Classification of Recommendations criteria described in the The Canadian Task 
Force on Preventive Health Care .47
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antenatal interventions have been identified that effectively 
decrease CP risk among preterm infants.
Magnesium Sulphate for Neuroprotection
In two studies published in the 1980s, preterm infants 
born to women with preeclampsia had a lower incidence 
of  adverse CNS outcomes than gestational age-matched 
neonates born to mothers without preeclampsia.18,19 In 
1995, a seminal case–control study20 was conducted with 
data derived from the California Cerebral Palsy project.21 
It demonstrated an association between antenatal 
magnesium sulphate administration prior to preterm 
birth and fewer cases of  CP among infants born < 1500 
g.20 It has been proposed that use of  magnesium sulphate 
for eclampsia treatment and prophylaxis may underlie the 
potential association between antenatal administration 
of  magnesium sulphate and CP,20,22 but the findings 
of  subsequent observational studies investigating the 
association have been inconsistent.23–25 Although the 
effectiveness of  magnesium sulphate for prevention and 
treatment of  maternal eclampsia is well proven, there 
remains a lack of  understanding of  how it may act as 
a neuroprotective agent.26,27 Magnesium acts in many 
intracellular processes, and its actions include cerebral 
vasodilation, reduction in inflammatory cytokines and/or 
oxygen free radicals, and/or inhibition of  calcium influx 
into cells.28,29 Animal studies have shown a neuroprotective 
effect.30,31
From 2002 to 2008, 5 randomized controlled trials (6145 
babies) studied magnesium sulphate for fetal neuroprotection 
(Table 2). In 2009, a milestone was reached with the 
publication of  3 meta-analyses, all of  which concluded that 
magnesium sulphate for fetal neuroprotection decreases 
the risk of  childhood CP.32–34 Four trials used magnesium 
sulphate specifically for fetal neuroprotection among women 
likely to deliver within 24 hours.35–38 The fifth trial26 evaluated 
the effectiveness of  magnesium sulphate for eclampsia 
prevention in women with preeclampsia. Of  the 4 trials 
with neuroprotective intent, one also included a tocolytic 
arm.37 Three of  these 4 trials enrolled primarily women with 
preterm labour (with or without PPROM),35–37 whereas the 
fourth focused on women with PPROM.38 Children were 
followed-up to the age of  2 years for CP assessment, and 3 
trials undertook cognitive testing.26,35,38
Study quality was good.32 Importantly, 4 of  the 5 trials 
(and all neuroprotective intent trials) described an adequate 
Table 2. Inclusion criteria in the randomized controlled trials of magnesium sulphate for fetal neuroprotection
Inclusion criteria*
Study
Women, 
n
Multiple
pregnancy, 
%
Gestational 
age, weeks
Delivery
likely within 
24 hours
PTL, 
% PPROM
Chorioam-
nionitis
Pre-
eclampsia
Severe 
IUGR APH
Neuroprotective intent 
ACTOMgSO4 
Crowther et al . 
200335
1062 17 < 30 Yes 63 9% 14% 15% 9% 14%
PREMAG Marrett  
et al . 200636
564 22 < 33 Yes 85 61% 11% Excluded Excluded 19%
MAGnet 
Mittendorf et al . 
2002—
neuroprotective 
intent arm37
57 4 25 to 33+6 NA 100† If 
associated 
with PTL
Excluded Excluded NA NA
BEAM Rouse  
et al . 200838 
2241 9 24 to 31+6 NA 10 87% NA Excluded Included 
by % NA
NA
Other primary intent
MAGnet Mittendorf 
et al . 2002, tocolytic 
arm37
92 15 25to 33+6 NA 100 If 
associated 
with PTL
Yes‡ Excluded NA Yes‡
MAGPIE 200641 10
141
4 < 37
  
NA NA NA NA 100% NA NA
LD: loading dose; NA: not available
* indications for at least 90% of study population listed .
† With cervical dilatation > 4 cm and therefore not eligible for tocolysis .
‡ 71 .1% had PPROM and 50 .8% had chorioamnionitis, but the results were not presented according to whether women were in the tocolytic or neuroprotective intent arms . 
(but subgroup analyses  
were possible for lower 
gestational age categories)
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method of  allocation concealment.26,35,36,38 All but the 
tocolytic arm of  Mittendorf  et al.37 described double-
masking of  outcome assessment.
Magnesium Sulphate Use in Obstetrics
Magnesium sulphate is widely available and commonly used 
in Canadian obstetric practice for eclampsia prophylaxis 
and treatment.26,27,39 Magnesium sulphate is no longer 
recommended for tocolysis, because it is ineffective.34
This document summarizes the relevant evidence and 
provides practice recommendations related to the use of  
antenatal magnesium sulphate for fetal neuroprotection 
among women with imminent preterm birth.
Summary Statement
1. “Imminent preterm birth” is defined as a high 
likelihood of  birth  due to one or both of  the 
following conditions (II-2):
 •  Active labour with ≥ 4 cm of  cervical dilation,   
•  with or without PPROM.
 •  Planned preterm birth for fetal or maternal  
•  indications.
Recommendation
1.   For women with imminent preterm birth  
(≤ 31+6 weeks), antenatal magnesium sulphate 
administration should be considered for fetal 
neuroprotection. (I-A)
Table 3a presents the results of  the 3 relevant meta-
analyses of  neuroprotective trials,32–34 and shows that 
antenatal magnesi um sulphate reduced the risk of  
“death or CP,” “death or moderate-severe CP,” “any CP,” 
 Table 3a. Magnesium sulphate versus placebo: perinatal outcomes in neuroprotection trials only
RR (95%CI) Trials, n, Infants, n
Doyle et al .34
Costantine  
and Weiner33
Conde-Agudelo 
and Romero32 Doyle et al .34
Costantine  
and Weiner33
Conde-Agudelo 
and Romero32
Primary outcomes
Death or CP 0 .85 
(0 .74 to 0 .98)
0 .86 
(0 .75 to 0 .99)
Not presented 4 trials, 
4446 infants
4 trials, 
4314 infants
Not presented 
Death or moderate-
severe CP
0 .85 
(0 .73 to 0 .99)
Not presented Not presented 3 trials, 
4250 infants
Not presented
Death or substantial 
gross motor dysfunction
0 .84 
(0 .71 to 1 .00)
Not presented Not presented 3 trials, 
4387 infants
Not presented Not presented
Death 0 .95 
(0 .80 to 1 .12)
0 .95 
(0 .80 to 1 .13)
0 .95 
(0 .80 to 1 .12)
4 trials, 
4446 infants
4 trials, 
4324 infants
4 trials, 
4446 infants
CP 0 .71 
(0 .55 to 0 .91)
0 .71 
(0 .55 to 0 .91)
0 .71 
(0 .55 to 0 .91)
4 trials, 
4446 infants
4 trials, 
4314 infants
4 trials, 
4446 infants
Moderate-severe CP Not presented 0 .60 
(0 .43 to 0 .84)
Not presented Not presented 3 trials, 
4250 infants
Not presented
Substantial gross motor 
dysfunction
0 .60 
(0 .43 to 0 .83)
Not presented Not presented 3 trials; 
4387 infants
Not presented Not presented
Any neurological 
impairment
1 .03 
(0 .87 to 1 .21)
Not presented Not presented 1 trial, 
1255 infants
Not presented Not presented
Other neonatal CNS outcomes
IVH 0 .96 
(0 .86 to 1 .07)
Not presented Not presented 4 trials to 
4446 infants
Not presented Not presented
Severe IVH  
(grade 3 or 4)
0 .83 
(0 .62 to 1 .13)
Not presented Not presented 2 trials; 
3699 infants
Not presented Not presented
PVL 0 .93 
(0 .68 to 1 .28)
Not presented Not presented 4 trials to 
4446 infants
Not presented Not presented
Other infant/child neurodevelopmental outcomes
Developmental delay or 
intellectual impairment
1 .00 
(0 .91 to 1 .09)
Not presented Not presented 3 trials, 
4387 infants
Not presented Not presented
Major neurological 
disability
1 .14 
(0 .86 to 1 .51)
Not presented 1 .09 
(0 .83 to 1 .43)
1 trial, 
1255 infants
Not presented 2 trials, 
2060 infants
Blindness 0 .97 
(0 .14 to 6 .90)
Not presented 0 .97 
(0 .14 to 6 .90)
2 trials, 
1943 infants
Not presented 2 trials, 
1943 infants
Deafness 0 .51 
(0 .05 to 4 .96)
Not presented 0 .51 
(0 .05 to 4 .96)
2 trials, 
1943 infants
Not presented 2 trials, 
1943 infants
 CNS: central nervous system; IVH: intraventricular hemorrhage; PVL: periventricular leukomalacia .
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“moderate-severe CP,” and “substantial gross motor 
dysfunction” (inability to walk without assistance) at 2 
years of  age. The direction of  effect was the same for 
death or substantial gross motor dysfunction, but this did 
not reach statistical significance. Results were consistent 
between trials and across the meta-analyses. Use of  
magnesium sulphate was not associated with an increase 
in pediatric death. The tocolytic arm of  one study37 was 
stopped early because of  an increase in pediatric mortality; 
although this is consistent with the effects of  magnesium 
sulphate administered as a tocolytic in other studies,34 
there were other quality issues with the Mittendorf  et 
al. tocolytic arm. These included the confounding effect 
of  multiple births (i.e., more in the magnesium sulphate 
arm), the low quality score (Jahad score of  2/8 when the 
other neuroprotective intent trials scored 7–8/8), the lack 
of  a placebo arm, that crossover was allowed, and that 3 
of  the 8 neonatal deaths in the magnesium sulphate arm 
were related to congenital anomalies (n = 1) or twin-to-
twin transfusion (n = 2).
When the tocolytic arm of  the MAGnet Trial40 and 
results of  the preeclampsia prophylaxis trial (MAGPIE)41 
were included in the meta-analyses, antenatal magnesium 
sulphate was shown to reduce the risk of  death or moderate-
severe CP, any CP, moderate-severe CP, and substantial 
gross motor dysfunction; the outcome of  death or CP no 
longer reached statistical significance (Table 3b). Although 
such analyses support the use of  magnesium sulphate to 
decrease CP, the results of  the neuroprotective intent trials 
suggest a change in clinical practice.
 Table 3b. Magnesium sulphate versus placebo: perinatal outcomes in all trials of antenatal magnesium sulphate 
Doyle et al .34 Costantine and Weiner33 Conde-Agudelo and Romero32
RR (95% CI)
Trials, n
Infants, n RR (95% CI)
Trials, n
 Infants n RR (95% CI)
Trials, n
 Infants n
Primary outcomes
Death or CP 0 .94 
(0 .78 to 1 .12)
5 trials, 
6145 infants
0 .92 
(0 .83 to 1 .03)
5 trials, 
5225 infants
0 .92 
(0 .83 to 1 .02)
5 trials, 
5357 infants
Death or moderate-
severe CP
Not presented Not presented 0 .85 
(0 .73 to 0 .99)
3 trials, 
4250 infants
Not presented Not presented
Death or substantial 
gross motor dysfunction
0 .92 
(0 .75 to 1 .12)
4 trials, 
5980 infants
 Not presented Not presented Not presented Not presented
Death 1 .01 
(0 .82 to 1 .23)
5 trials, 
6145 infants
0 .95 
(0 .80 to 1 .13)
4 trials, 
4324 infants
1 .01 
(0 .89 to 1 .14)
5 trials, 
5357 infants
CP 0 .69 
(0 .54 to 0 .87)
5 trials, 
6145 infants
0 .71 
(0 .55 to 0 .91)
4 trials, 
4314 infants
0 .69 
(0 .55 to 0 .88)
5 trials, 
5357 infants
Moderate-severe CP Not presented Not presented 0 .60 
(0 .43 to 0 .84)
3 trials, 
4250 infants
0 .64 
(0 .44 to 0 .92)
3 trials, 
4387 infants
Substantial gross motor 
dysfunction
0 .60 
(0 .43 to 0 .83)
4 trials, 
4387 infants
Not presented Not presented 0 .60 
(0 .43 to 0 .83)
3 trials, 
4387 infants
Any neurological 
impairment
1 .01 
( 0 .86 to 1 .19 )
2 trials, 
2848 infants
Not presented Not presented 1 .02 
(0 .86 to 1 .20)
2 trials, 
2060 infants
Other neonatal CNS outcomes
IVH 0 .96 
(0 .86 to 1 .08)
4 trials, 
4552 infants
Not presented Not presented 0 .96 
(0 .86 to 1 .08))
5 trials, 
4552 infants
Severe IVH (grade 3/4) 0 .83 
(0 .62 to 1 .13)
2 trials, 
3699 infants
Not presented Not presented 0 .83 
(0 .61 to 1 .11)
4 trials, 
3864 infants
PVL 0 .93 
(0 .68 to 1 .28)
4 trials, 
4552 infants
Not presented Not presented 0 .93 
(0 .68 to 1 .28)
5 trials, 
4552 infants
Other infant/child neurodevelopmental outcomes
Developmental delay or 
intellectual impairment
0 .99 
(0 .91 to 1 .09)
4 trials, 
5980 infants
Not presented Not presented Not presented Not presented
Major neurological 
disability
1 .07 
(0 .82 to 1 .40)
2 trials, 
2848 infants
Not presented Not presented 1 .09 
(0 .83 to 1 .43)
2 trials, 
2060 infants
Blindness 0 .74 
(0 .17 to 3 .30)
3 trials, 
3536 infants
Not presented Not presented 0 .97 
(0 .14 to 6 .90)
2 trials, 
1943 infants
Deafness 0 .79 
(0 .24 to 2 .56)
3 trials, 
3536 infants
Not presented Not presented 0 .51 
(0 .05 to 4 .96)
2 trials, 
1943 infants
CNS: central nervous system; IVH: intraventricular hemorrhage; PVL: periventricular leukomalacia .
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For antenatal magnesium sulphate given specifically for fetal 
neuroprotection, the NNT to prevent one case of  death or 
CP is 43 (based on an event rate of  14.9% overall in the 
magnesium arm of  trials and 17.2% among placebo-treated 
controls). The NNT to prevent one case of  CP is 63 (based 
on an event rate of  3.4% overall in the magnesium arm 
of  the trials and 5.0% among placebo-treated controls). 
These compare favourably with other established obstetric 
interventions, such as the NNT of  50 (95% CI 34 to 100) 
for use of  magnesium sulphate to prevent eclampsia among 
women with severe preeclampsia.26
While the 3 meta-analyses demonstrate significant results for 
antenatal magnesium sulphate reducing the risk of  death or 
CP, death or moderate-severe CP, any CP, moderate-severe 
CP, and substantial gross motor dysfunction at 2 years of  
age, it is important to note that no single trial demonstrated 
a statistically significant decrease in the combined outcome 
of  death or CP.
Despite these favourable results, strong evidence is lacking 
with respect to 4 clinical issues: 
1. The gestational age below which this therapy should be 
offered.
2. The optimal loading and maintenance doses. 
3. Antenatal magnesium sulphate has not been 
associated with a decrease in central nervous 
system pathology associated with CP, cognitive 
impairment (i.e., intraventricular hemorrhage or 
white matter injury measured as cystic periventricular 
leukomalacia), and other adverse developmental 
outcomes associated with preterm birth (e.g., 
developmental delay, neurological impairment, 
blindness, or deafness). However, confidence 
intervals in these trials35–38 were reasonably wide and 
compatible with any of  the following: a protective 
effect (38% reduction), harmful effect (13% increase), 
or no effect at all. Further evidence is needed to 
determine whether there is an association between 
magnesium sulphate and decreased CNS pathology. 
4. There is no information on the effect of  magnesium 
sulphate on learning disabilities, school difficulties, or 
other common school-age disabilities, because none 
of  the trials reported on outcomes beyond 2 years of  
age; follow-up to school-age is planned for 2 of  the 
trials.35,36 Neurological follow-up was conducted to the 
age of  2 years in 3 trials, 2 of  which undertook detailed 
neurocognitive testing.35,38 However, learning disabilities 
and developmental coordination disorder, which are 
prevalent among extremely low birth weight babies born 
preterm, cannot be reliably detected until school age.
Recommendations
2. Although there is controversy about upper 
gestational age, antenatal magnesium sulphate for 
fetal neuroprotection should be considered from 
viability to ≤ 31+6 weeks. (II-1B)
3. If  antenatal magnesium sulphate has been started 
for fetal neuroprotection, tocolysis should be 
discontinued. (III-A)
There is some uncertainty about the gestational age at 
which magnesium sulphate should be administered. 
A lower gestational age limit for viability has not been 
specified in these studies35,37 so that clinical decisions 
can take into consideration both parental preference and 
institutionally defined thresholds. Each of  the trials in the 
meta-analyses32–34 had a different upper gestational age 
limit for study eligibility, ranging from < 30 weeks35 to 
≤ 33+6,37 making it challenging to recommend an upper 
age limit.
It is uncertain whether the neuroprotective effect of  
magnesium sulphate depends on gestational age at birth. 
Table 4a presents the results of  trials with neuroprotective 
intent. The outcome of  death or CP was significantly 
decreased by magnesium sulphate when therapy was 
administered at < 34 weeks. The outcome of  CP was 
significantly decreased at all gestational ages. Results for 
all trials are shown in Table 4b; the < 30 week and < 28 
week analyses include post hoc analyses of  the MAGPIE 
and BEAM trials, as randomization was not stratified by 
these gestational age groupings. No effect of  magnesium 
sulphate was seen on the outcome of  death or CP, but CP 
was significantly decreased at all gestational ages.
There are 2 key considerations when determining a 
gestational cut-off: (1) the potential for effect modification 
by gestational age (i.e., the potential for magnesium sulphate 
to have a different effect at different gestational ages), and 
(2) the baseline prevalence of  CP at different gestational 
ages (since the NNT will be lower with a higher baseline 
prevalence of  a disease). Table 4a (neuroprotective intent 
trials) and Table 4b (all relevant trials) both show that the 
point estimate for the effect of  magnesium sulphate on CP 
risk reduction appears to be lower at < 28 weeks. Since the 
prevalence of  CP is also higher at < 28 weeks, the NNT to 
prevent one case of  CP is lowest at < 28 weeks. The NNT 
appears to fall for administration of  magnesium at earlier 
gestational ages, with a more obvious trend among all trials 
rather than among only neuroprotective trials. Regardless, 
the NNT to prevent one case of  CP is low at all gestational 
ages at < 34 weeks.
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A more useful post hoc analysis would be to examine CP risk 
reduction within gestational age strata (32 to 33 weeks, 30 
to 31 weeks, 28 to 29 weeks, and < 28 weeks) to identify the 
gestational age at which babies may be most likely to benefit. 
In the BEAM trial,38 analyses were stratified by gestational 
age (< 28 vs. 28 to 31 weeks). Although it appeared as if  
the decrease in CP was confined to the < 28-week subgroup, 
the test for interaction by gestational age was actually not 
significant. This should be interpreted as revealing no 
difference in magnesium effect on CP rate by gestational 
age up to 31+6 weeks. In MAGPIE,41 which was not a 
neuroprotective intent trial and which underreported CP, 
CP risk was similar at < 30 weeks (RR 1.04; 95% CI 0.06 to 
16.06) and at 30 to 33 weeks (RR 0.95; 95% CI 0.71 to 1.27).
In summary, CP risk is highest at earlier gestational ages, 
but these very preterm infants are fewer in number. Use 
of  magnesium sulphate at gestational ages closer to 34 
weeks has the potential to substantially increase overuse of  
magnesium sulphate for women with threatened preterm 
birth who do not deliver in the subsequent 24 to 48 hours. 
Therefore, consensus was reached to recommend an upper 
gestational age cut-off  of  < 32 weeks (i.e., ≤ 31+6 weeks) 
to strike a balance between appropriate use of  magnesium 
sulphate at earlier gestational ages and potential overuse 
of  magnesium sulphate at later gestational ages, when 
neurological morbidity is lower. Institutions may choose 
different thresholds (< 34 weeks) according to other 
considerations, including the accuracy of  gestational age 
determination and resource allocation.
Table 2 presents the baseline characteristics of  women who 
were enrolled in the relevant randomized controlled trials. 
In 3 of  the 4 neuroprotective intent trials, most women 
had preterm labour with anticipated delivery within 24 
hours. This is not equivalent to threatened preterm labour 
for which tocolysis is an option in the hope/expectation 
of  being able to arrest labour; this must be emphasized 
to prevent potential overuse of  magnesium sulphate for 
neuroprotection in patients who are not truly in labour. The 
other major indications for very preterm delivery (APH or 
IUGR) were present in a minority of  women enrolled in the 
relevant trials. Although many women also had PPROM, 
only the BEAM trial38 enrolled women with PPROM 
without associated preterm labour. In this guideline, 
these women are not included as eligible for magnesium 
sulphate for neuroprotection. First, in the BEAM trial, re-
treatment with magnesium was administered for 59.1% 
of  women. Second, women with PPROM who are not in 
labour are not necessarily in a delivery suite and receiving 
one-to-one nursing care; administration of  magnesium 
for neuroprotective intent could have significant hospital 
resource implications for these women.
All trials excluded women with the usual contraindications to 
magnesium sulphate (i.e., hypersensitivity to the drug, hepatic 
Table 4a. Subgroup analyses by gestational age at randomization: neuroprotective trials only35–38
RR (95% CI) NNT to prevent harm
Weeks Death or CP CP Death or CP CP Trials, n, infants, n
< 34 0 .85 (0 .74 to 0 .98) 0 .71 (0 .55 to 0 .91) 43 53 5 trials, 6145 infants
< 32 0 .86 (0 .74 to 1 .00) 0 .68 (0 .52 to 0 .91) 43 50 3 trials, 3981 infants
< 30* 0 .87 (0 .74 to 1 .03) 0 .69 (0 .48 to 0 .99) 36 53† 3 trials, 2475 infants
< 28* 0 .95 (0 .74 to 1 .22) 0 .45 (0 .23 to 0 .87) 91 30 1 trial, 938 infants
* Includes the < 28 week subgroup of Rouse et al .38 which had women as the denominator .
† Inclusion of only the Crowther et al .35 trial and exclusion of the BEAM data (Rouse et al .38) give an NNT of 24 .
 Table 4b. Subgroup analyses by gestational age at randomization: all trials26,35-38,41
RR (95% CI) NNT to prevent harm
Weeks Death or CP CP Death or CP CP Trials, n, infants, n
< 34 0 .94 (0 .78 to 1 .12) 0 .68 (0 .54 to 0 .87) 105 63 5 trials, 6145 infants
< 32 0 .95 (0 .76 to 1 .18) 0 .69 (0 .52 to 0 .91) 71 56 3 trials, 3981 infants
< 30* 0 .97 (0 .78 to 1 .21) 0 .70 (0 .49 to 0 .99) 71 56† 3 trials, 2475 infants
< 28* 0 .95 (0 .74 to 1 .22) 0 .45 (0 .23 to 0 .87) 91 30 1 trial, 938 infants
* Includes the < 28 week subgroup of Rouse et al .,38 which had women as the denominator .
  This also includes the < 30 week subgroup data provided by the MAGPIE trial .
† In the Cochrane review,34 the < 30 week subgroup did not include the BEAM trial data for < 28 week38 and the NNT was 50 .
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coma, myasthenia gravis) and those whose fetus was unlikely 
to benefit from potential neuroprotection (i.e., severe fetal 
malformations or chromosomal abnormalities). Antenatal 
magnesium sulphate for fetal neuroprotection should be 
used with caution in women who have renal impairment, and 
serum magnesium levels should be monitored.
Magnesium sulphate for neuroprotection should be 
administered regardless of  singleton or multiple gestation, as 
women with multiple pregnancies were enrolled in all trials.
The inclusion and exclusion criteria from the published 
trials are summarized in Table 5.
Recommendations
4. Magnesium sulphate should be discontinued if  
delivery is no longer imminent or a maximum of  24 
hours of  therapy has been administered. (II-2B)
5. For women with imminent preterm birth, antenatal 
magnesium sulphate for fetal neuroprotection 
should be administered as a 4g IV loading dose, 
over 30 minutes, followed by a 1g/hr maintenance 
infusion until birth. (II-2B)
6. For planned preterm birth for fetal or maternal 
indications, magnesium sulphate should be started, 
ideally within 4 hours before birth, as a 4g IV 
loading dose, over 30 minutes, followed by a 1g/hr 
maintenance infusion until birth. (II-2B)
As shown in Table 6, 4 trials of  magnesium sulphate 
administered a 4 g IV loading dose over 20 to 30 min35–37,41 
Maintenance dosing varied from none36,37 to 1 g/hr35,41 or 
2 g/hr38 for 12 hr38 or 24 hr.35,41 The median dose received 
was as high as 31.5 g (IQR of  29.0 to 44.6), but this was the 
trial primarily of  women who had PPROM without labour, 
and 59.1% of  women were re-treated when delivery was 
again considered to be imminent.38 The median dose was 
much lower, at 6.5 g (IQR of  4.5 to 14.0 g),35 when women 
were enrolled primarily for preterm labour, reflecting a very 
short median time from enrolment to delivery.
There have been no direct comparisons of  different dosing 
regimens of  magnesium sulphate for neuroprotection. 
A loading dose of  4 g IV with a maintenance infusion of  
1 g/hr has been recommended to (1) resemble current 
clinical practice and hospital protocols for magnesium 
sulphate for eclampsia prophylaxis and treatment, and 
(2) minimize concerns about maternal safety, particularly as 
higher dosing regimens have not been associated with greater 
neuroprotection. Trials that administered maintenance 
infusions treated for a maximum of  24 hours antenatally.
For women with planned preterm birth, for fetal or 
maternal indications, it is recommended that magnesium 
sulphate be started as close as possible to 4 hours before 
birth, as this was the mean time from randomization to 
birth in subgroup analysis.35 No trials randomized women 
with planned preterm birth to different durations of  
magnesium sulphate therapy.
Risk of  medication errors may be decreased if  magnesium 
sulphate is prepared in the central pharmacy rather than in 
the labour and delivery suite.
Magnesium sulphate for fetal neuroprotection should be 
discontinued at delivery.
The one trial (Rouse et al.38) in which re-treatment was 
performed enrolled primarily women who had PPROM 
without labour, and 59.1% of  women were re-treated when 
delivery was again considered to be imminent.38
Magnesium sulphate was infused for neuroprotective intent 
as quickly as 20 minutes before delivery.
Recommendations
7. There is insufficient evidence that a repeat 
course of  antenatal magnesium sulphate for fetal 
neuroprotection should be administered. (III-L)
8. Delivery should not be delayed in order to 
administer antenatal magnesium sulphate for fetal 
neuroprotection if  there are maternal and/or fetal 
indications for emergency delivery. (III-E)
9. When magnesium sulphate is given for fetal 
neuroprotection, maternity care providers should 
use existing protocols to monitor women who are 
receiving magnesium sulphate for preeclampsia/
eclampsia. (III-A)
Existing protocols developed for eclampsia prophylaxis 
and treatment may be used for women given magnesium 
sulphate for fetal neuroprotection. Close monitoring of  
 Table 5. Inclusion and exclusion criteria for antenatal 
magnesium sulphate administration in randomized 
controlled trials
Inclusion criteria Exclusion criteria 
Singleton and multiple 
pregnancies
Magnesium sulphate already 
administered for preeclampsia/
eclampsia
Nulliparous and parous < 12 hours since discontinuation 
of previous magnesium sulphate 
infusion
Anticipated vaginal or 
Caesarean delivery
Magnesium sulphate 
contraindicated
Any reason for anticipated 
preterm birth
Fetus unlikely to benefit
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maternal urine output should not be required to the same 
degree (i.e., no requirement for Foley catheter) when 
magnesium sulphate is given with neuroprotective intent.
Magnesium sulphate produces peripheral vasodilation 
when infused intravenously. In neuroprotective intent 
trials, dose-related effects were common, particularly 
flushing, problems at the injection site, sweating, and 
nausea and vomiting (Table 7). Serious maternal side effects 
were uncommon, with only maternal hypotension and 
tachycardia reaching statistical significance. Few women 
discontinued magnesium sulphate because of  side effects. 
Neither maternal death nor cardiorespiratory arrest was 
reported in the magnesium sulphate arm of  these trials.
Monitoring of  maternal serum magnesium levels is not 
required when magnesium sulphate is administered solely 
for fetal neuroprotection. Maternal adverse effects are 
dose-related, with respiratory or cardiac arrest associated 
with levels in excess of  5 mmol/L. Levels of  this magnitude 
are not anticipated when magnesium contraindications are 
observed but are more frequent when magnesium sulphate 
is prepared in the delivery suite rather than by a central 
pharmacy.
Because of  their underlying condition, women with 
imminent preterm birth require continuous fetal heart rate 
monitoring, in accordance with the SOGC fetal health 
surveillance guidelines.42
   Recommendations
  10. Indications for fetal heart rate monitoring in 
women receiving antenatal magnesium sulphate for 
neuroprotection should follow the fetal surveillance 
recommendations of  the SOGC’s 2007 Fetal Health 
Surveillance: Antepartum and Intrapartum Consensus 
Guideline. (III-A)
  11. Since magnesium sulphate has the potential to 
alter the neonate’s neurological evaluation, causing 
hypotonia or apnea, health care providers caring for 
the neonate should have an increased awareness of  
this effect. (III-C)
 
 
 
 
 
 
       
 
                                               YES                               NO 
 
 
          
 
 
 
 
 
 
Woman ≤ 31+6 weeks gestation AND imminent 
preterm birth 
  
• Active labour with ≥ 4 cm cervical dilation with either failure or 
contraindication to tocolysis 
• ≥ 4 cm dilation with documented progressive change in cervical 
dilation   
• PPROM with active labour  
• Planned delivery for fetal or maternal indications 
• Administer MgSO4 loading dose,      
4g IV over 30 minutes 
• Follow with MgSO4 maintenance 
infusion of 1g/hour IV until birth or a 
maximum of 24 hours of therapy 
• Administer corticosteroids for fetal 
lung maturation (if not already given) 
• Monitor maternal vital signs as per 
existing MgSO4 protocols 
• Provide continuous fetal heart 
surveillance  
Woman currently not eligible for 
MgSO4 for neuroprotection  
CLINICAL TIPS 
• MgSO4 may be administered before tocolytic drugs have been cleared from the maternal  
circulation. If nifedipine has been used for tocolysis or hypertension, there is NO  
contraindication to the use of MgSO4 for fetal neuroprotection. 
• Delivery should NOT be delayed in order to administer antenatal MgSO  for fetal  
  neuroprotection if there are maternal and/or fetal indications for urgent delivery.   
• Monitoring of serum Mg levels is NOT required. 
4
Magnesium sulphate for fetal neuroprotection in imminent preterm birth  
(≤ 31+6 weeks)
“Imminent preterm birth” is defined as a high likelihood of birth, due to one or both of the following conditions: active 
labour with ≥4 cm of cervical dilation, with or without PPROM; planned preterm birth for fetal or maternal indications .
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The relevant randomized controlled trials34 raise no concerns 
about short-term neonatal adverse effects of  antenatal 
exposure, and no additional neonatal assessment or care 
is required. Neonates with hypermagnesemia may present 
with symptoms of  apnea or hypoventilation, weakness, 
hypotonia, absent or reduced deep tendon reflexes, and 
stupor or coma. This symptom complex has been described 
in the neonates of  mothers administered large doses of  IV 
magnesium sulphate for eclampsia with neonatal serum 
levels > 4.5 mEq/L.43 However, antenatal magnesium sul-
phate administered specifically for fetal neuroprotection did 
not affect the incidence of  Apgar score < 7 at 5 minutes 
(RR 1.03; 95% CI 0.90 to 1.18; 3 trials, 4387 infants), 
neonatal hypotonia (RR 1.02; 95% CI 0.77 to 1.36; 1 trial, 
2444 infants), or the need for ongoing ventilatory support 
(RR 0.94; 95% CI 0.89 to 1.00; 3 trials; 4387 women). None 
of  the main trial publications reported on the need for active 
resuscitation at birth,34 but a subanalysis of  the BEAM trial 
found no correlation between cord blood magnesium levels 
and the need for bag-mask ventilation, intubation, or chest 
compressions.44 It is unknown whether magnesium sulphate 
exposure would affect the need for ventilation in neonatal 
intensive care units using protocols to minimize ventilation.
The relevant randomized controlled trials35–38 demonstrated 
no other differences in neonatal morbidity, including 
seizures, respiratory distress syndrome, bronchopulmonary 
dysplasia, or necrotizing enterocolitis.
Few newborn subjects with in utero exposure to magnesium 
sulphate remote from delivery were included in the 
relevant trials. There is no clear rationale for any additional 
assessment of  these newborns.
There should be an ongoing registry of  children exposed 
to antenatal magnesium sulphate for neuroprotection. This 
would allow evaluation of  the following:
1. Effects on delivery room resuscitation, especially in 
units with ventilation-avoidance protocols
2. Anticipated reduction in CP
3. Effect on the high prevalence of  school age morbidities 
among infants born preterm.
SPECIAL CONSIDERATIONS REGARDING  
THE USE OF MAGNESIUM SULPHATE  
FOR FETAL NEUROPROTECTION
Transport
When maternal transport is being considered, magnesium 
administration should be decided on in consultation with 
the receiving centre, on a case-by-case basis.
Drug Interactions
Antenatal corticosteroids should be administered for fetal 
lung maturation.
When tocolysis has been employed to attempt to arrest 
preterm labour, magnesium sulphate can be used once 
Table 6. Magnesium sulphate dosing in the randomized controlled trials of magnesium sulphate for fetal 
neuroprotection 
Intervention: MgSO4 Women who Median (IQR) dose
Study Women, n Loading dose received the LD, % Maintenance dose received (g)
Neuroprotective intent 
ACTOMgSO4 
Crowther et al . 200335
1062 4g IV over 20 mins 90% 1g/hr IV for 24 hr or 
until delivery, whichever 
comes first
6 .5 (4 .5, 14)
PREMAG Marrett et al . 
200636
564 4g IV over 30 mins 99% None given 4 g IV over 30 mins 
MAGnet Mittendorf et al . 
2002—neuroprotective 
intent arm37
57 4g IV bolus Not reported Neuroprotective arm: 
none
(Tocolysis arm: 2–3g/hr)
Not reported
BEAM Rouse et al . 200838 2241 6g IV over 
20–30 mins*
> 90%† 2 g/hr IV for a maximum 
of 12 hr or until delivery†
31 .5 (29 .0, 44 .6)
Other primary intent
MAGnet Mittendorf et al . 
2002—tocolytic arm37
92 4g IV “bolus” Not known 2–3 g/hr Not reported
MAGPIE 200641 10 141 4g IV over 
10 to15 mins
96% 1g/hr IV (or 5g/4hrs IM) 
for 24 hours
18 (9, 29)‡ 
LD: loading dose; NA: not available .
* 71 .5% of women were eligible for re-treatment . 59 .1% of women were re-treated and were on magnesium sulphate at delivery .
† Based on the fact that 91% of women were on magnesium sulphate for at least three hours .
‡ Estimated as value uncertain from published data .33
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tocolysis has been discontinued because delivery is 
considered imminent. If  nifedipine has been used for 
tocolysis or hypertension, there is no contraindication to 
the use of  magnesium sulphate for fetal neuroprotection. 
Although case reports have described neuromuscular 
blockade with concomitant use of  magnesium sulphate and 
nifedipine or other calcium channel blockers, a controlled 
study and synthesis of  the literature failed to demonstrate 
an increased risk.42
Potential Obstetrical Adverse Outcomes
In the Conde-Agudelo and Romero meta-analysis,32 mag-
nesium sulphate given with neuroprotective intent was not 
associated with a difference in Caesarean section (822 [42.9%] 
in the magnesium arm vs. 834 [42.8%] for placebo; RR 1.0; 
95% CI 0.9 to 1.1; 3 trials, 3867 women) or severe 
postpartum hemorrhage (28 [3.4%] in the magnesium 
arm vs. 26 [3.2%] for placebo; RR 1.1; 95% CI 0.6 to 1.8; 
2 trials, 1626 women). None of  the trials reported on length 
of  labour or augmentation of  labour.
CLINICAL PRACTICE GUIDELINES  
AND COMMITTEE OPINION
Australian National Clinical Practice Guidelines45 were 
published in March 2010 by the Antenatal Magnesium 
Sulphate for Neuroprotection Guideline Development 
Panel. They recommended antenatal magnesium sulphate 
for fetal neuroprotection (excellent evidence) in the same 
dosage as recommended in these guidelines. However, 
magnesium was recommended only at < 30 weeks’ gestation 
(good evidence) on the basis of  two considerations. First, 
no one gestational age subgroup (of  the < 34, < 33, < 32, 
and < 30 week categories considered) was considered to 
show a clear benefit, although the < 28 week subgroup of  
Rouse et al.38 was not included, because the committee felt 
that the predominance of  PPROM in that study population 
limited generalizability to the target population of  women 
with imminent preterm labour (which the committee 
defined as planned or definitely expected within 24 hours). 
Second, in the face of  uncertainty, the committee felt it 
was prudent to limit the impact of  their clinical practice 
guidelines on resource allocation.
Also in March 2010, the American College of  Obstetricians 
and Gynecologists issued a committee opinion on magnesium 
sulphate for fetal neuroprotection. It  stated that “the 
available evidence suggests that magnesium sulphate given 
before anticipated early preterm birth reduces the risk of  
cerebral palsy in surviving infants.” No official opinion was 
given on a gestational age cut-off, but it was recommended 
that physicians develop specific guidelines around the issues 
of  inclusion criteria, dosage, concurrent tocolysis, and 
monitoring in accordance with one of  the larger trials.46
Table 7. Maternal outcomes in trials of magnesium sulphate for fetal neuroprotection in 
neuroprotective intent trials (adapted from Conde-Agudelo and Romero32)
MgSO4
n (%)
Placebo
n (%) RR (95% CI)
Trials
n
Clinical and self-assessed maternal side effects
Any side effect 1356/1917 (70 .7) 343/1950 (17 .6) 5 .05 (2 .06 to 12 .39) 3
Minor side effects
Flushing 1119/1917 (58 .4) 162/1950 (8 .3) 7 .56 (3 .39 to 16 .88) 3
Problems at injection site 614/1631 (37 .6) 68/1672 (4 .1) 9 .12 (7 .19 to 11 .57) 2
Sweating 411/1631 (25 .2) 57/1672 (3 .4) 6 .37 (1 .96 to 20 .68) 2
Nausea or vomiting 312/1917 (16 .3) 76/1950 (3 .9) 4 .60 (1 .54 to 13 .75) 3
Serious side effects
Hypotension 80/821 (9 .7) 52/805 (6 .5) 1 .51 (1 .09 to 2 .09) 2
Tachycardia 56/535 (10 .5) 36/527 (6 .8) 1 .53 (1 .03 to 2 .29) 1
Respiratory depression 41/1631 (2 .5) 31/1672 (1 .9) 1 .31 (0 .83 to 2 .07) 2
Pulmonary edema 8/1096 (0 .7) 3/1145 (0 .3) 2 .79 (0 .74 to 10 .47) 1
Infusion stopped due to adverse effects 123/1631 (7 .5) 44/1672 (2 .6) 2 .81 (2 .01 to 3 .93) 2
Serious maternal adverse effects
Death 0/1917 1/1950 0 .32 (0 .01 to 7 .92) 3
Cardiac or respiratory arrest 0/1917 0/1950 —* 3
* Not estimable .
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